Patients will receive intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles + itraconazole 200 mg oral tablet daily, on a 21-day cycle.
Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes

Patients will receive intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles.
Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes

Lung Cancer

itraconazole 200 mg oral tablet daily, on a 21-day cycle.

Itraconazole 200 mg

intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles.
Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes

Chemotherapy

oncology department Ain shams university

Itraconazole in Non Small Cell Lung Cancer

The Effect of Itraconazole on the Clinical Outcomes of Patients With Advanced Non Small Cell Lung Cancer Receiving Platinum Based Chemotherapy

time from treatment initiation to either progression, death from any cause or lost to follow up.

time in months from time of diagnosis to death or date of last contact.

To compare radiological response of patients with advanced lung cancer receiving platinum bases chemotherapy combined with itraconazole to those receiving platinum based chemotherapy only after 3 and 6 cycles of chemotherapy.

Patient's quality of life will be assessed at baseline, after 3 cycles, and at the end of chemotherapy treatment using EORTC modules specific to lung cancer.

Incidence and severity will be evaluated using National Cancer Institute-Common Toxicity Criteria for adverse events (CTCAE V4.03).

According to the sharing protocol of the official affliation

Asmaa Waheed Mohamed Mostafa

Doctor

Ain Shams University

Interventional, Randomized, Controlled, Prospective, Open label, Phase II study.

The intervention will only involve a single treatment with ablative fractional carbon dioxide laser therapy. The investigators will specifically be using the CO2RE® (Syneron Candela Corp, Wayland, MA).

Leg Ulcer

The intervention will include a single treatment of a lower extremity wound with ablative fractional carbon dioxide laser after MMS surgery.

CO2RE® (Syneron Candela Corp, Wayland, MA)

A physician who is not blinded will perform a sham laser treatment on blinded subjects.

Sham laser treatment

Saint Louis University

Evaluating the Safety and Efficacy of Fractionated Carbon Dioxide Therapy in Postoperative Lower Extremity Wound Healing

A Single Center, Prospective, Double-blinded, Randomized, Placebo-controlled Trial Evaluating the Efficacy of Fractionated Carbon Dioxide Therapy in Postoperative Lower Extremity Wound Healing

Score on the EQ-5D-5L. This is a quality of life questionnaire where higher scores equate to a better quality of life.

Time, in weeks, till complete wound healing in days. Complete wound healing is defined by reepithelization of the wound.

Wound temperature will be recorded in degrees Celsius through an infrared camera.

Ramona Behshad, MD

Assistant Professor Department of Dermatology

St. Louis University

Cancer of Head and Neck

Head and Neck Neoplasms

We will introduce a pretherapy [18F]-FMISO PET-CT in the treatment planning of patients suffering of head and neck cancer and eligible to a radical treatment with curative intent, consisting of conformational radiotherapy with or without chemotherapy or associated targeted therapy. [18F]-FMISO PET-CT results will not be taken into account for the patients' management. We will test different acquisition protocols and use a wild panel of quantification parameters issued from published studies and originals 'one developed by our team enable to describe [18F]-FMISO uptake. Patients will be followed clinically and para-clinically during two years after the end of the treatment according to the edited recommendations of these tumours type and grade to analyze outcome.

Positon Emission Tomography using 18F-FMISO

CHU de Bordeaux - Hôpital Pellegrin

Hôpital Robert Picqué

Prognostic Evaluation of 18fmiso Pet-ct in Head and Neck Cancer

Prognostic Evaluation of Fluor 18 Labelled FLUROMISONIDAZOLE (18F-FMISO) Positon Emission Tomography-Computed Tomography (PET-CT) in Head and Neck Squamous Cell Carcinomas

University Hospital, Bordeaux

Silver, in its common ionic (active) form (Ag+), is particularly attractive as an antibacterial agent because it can be readily incorporated into dressing materials. Silver-dressing are wound products designed to control infection and provide a wound environment conducive to management exudates, pain, and malodour.

Head and Neck Cancer

Wounds

Ulcer

Experimental group are accepted primary dressing the AQUACEL Ag. control group are provided with the AQUACEL on the wound surface. Wound specialist or primary nurses undertaking wound care are informed by inclusion criteria that the treatment shall be adhered to during the two-week study period.All wounds are cleansed with sterile saline prior to assessment and dressing application.The sterile, non-woven sodium carboxymethylcellulose primary AQUACEL Ag with 1.2% ionic silver.Each secondary dressing is covered a sterile gauze.Dressings are changed between daily assessments when judged necessary.Patients attended the wound ward weekly for treatment evaluation. All participating clinics used the same wound management guidelines and data collection forms.

skin neoplasms/hypoxia

Itraconazole in Non Small Cell Lung Cancer

Evaluating the Safety and Efficacy of Fractionated Carbon Dioxide Therapy in Postoperative Lower Extremity Wound Healing

Prognostic Evaluation of 18fmiso Pet-ct in Head and Neck Cancer

The Effect on an Ionic Silver Dressing in Head and Neck Patients With Malignant Fungating Wound

Najkompletnija baza ljekovitog bilja potpomognuta znanošću